Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Priyankana, Mishra"'
Autor:
Elliana Young, Amal Melhem-Bertrandt, James L. Murray, Vicente Valero, Gabriel N. Hortobagyi, Francisco J. Esteva, Ankur Varma, Rashmi Krishna Murthy, Stacy Moulder, D. J. Booser, Priyankana Mishra, Kimberly B. Koenig, Sharon H. Giordano, Kenneth R. Hess
Publikováno v:
Cancer. 120:1932-1938
BACKGROUND The purpose of the current study was to describe the outcomes of patients with human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified (HER2+) early breast cancer who received adjuvant or neoadjuvant trastuzumab-based thera
Autor:
Rashmi K, Murthy, Ankur, Varma, Priyankana, Mishra, Kenneth R, Hess, Elliana, Young, James L, Murray, Kimberly H, Koenig, Stacy L, Moulder, Amal, Melhem-Bertrandt, Sharon H, Giordano, Daniel, Booser, Vicente, Valero, Gabriel N, Hortobagyi, Francisco J, Esteva
Publikováno v:
Cancer. 120(13)
The purpose of the current study was to describe the outcomes of patients with human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified (HER2+) early breast cancer who received adjuvant or neoadjuvant trastuzumab-based therapy and were
Autor:
Gabriel N. Hortobagyi, Priyankana Mishra, Kenneth R. Hess, Marjorie C. Green, Francisco J. Esteva, Amal Melhem-Bertrandt, Vicente Valero, Kimberly Koenig, Ankur Varma, Daniel J. Booser, Rashmi Krishna Murthy, Stacy L. Moulder, Elliana J. Young, James L. Murray
Publikováno v:
Journal of Clinical Oncology. 30:527-527
527 Background: Trastuzumab (T) was approved for the adjuvant treatment of women with early-stage, HER-2 overexpressing (HER2+) breast cancer in 2006. There are limited data outlining the outcomes of patients with HER2+ breast cancer who receive adju
Autor:
Anthony Lucci, Mandar Karhade, Carolyn S. Hall, Savitri Krishnamurthy, Isabelle Bedrosian, A. Anderson, Henry Mark Kuerer, Priyankana Mishra
Publikováno v:
Breast Cancer Research and Treatment
Circulating tumor cells (CTCs) can be identified in approximately 25 % of stage I-III breast cancer patients; CTCs presence is a predictor of poor outcome in metastatic breast cancer, but little is known regarding the prognostic significance of CTCs